Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.
Amado RG, et al.
J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.
J Clin Oncol. 2008.
PMID: 18316791
Free article.
Clinical Trial.